Age could be either directly contributing to the higher S+D risk in CAS-treated patients or alternatively it could be associated with other factors that in turn are the true contributors to Background and Purpose-There is higher combined risk of stroke or death (S+D) at older ages with carotid stenting. We assess whether this can be attributed to patient or arterial characteristics that are in the pathway between older age and higher risk. Methods-Mediation analysis of selected patient (hypertension, diabetes mellitus, and dyslipidemia) and arterial characteristics assessed at the clinical sites and the core laboratory (plaque length, eccentric plaque, ulcerated plaque, percent stenosis, peak systolic velocity, and location) was performed in 1123 carotid artery stenting-treated patients in the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST). We assessed the association of age with these characteristics, the association of these characteristics with stroke risk, and the amount of mediation of the association of age on the combined risk of periprocedural S+D with adjustment for these factors. Results-Only plaque length as measured at the sites increased with age, was associated with increased S+D risk and significantly mediated the association of age on S+D risk. However, adjustment for plaque length attenuated the increased risk per 10 years of age from 1.72 (95% confidence interval, 1.26-2.37) to 1.66 (95% confidence interval, 1.20-2.29), accounting for only 8% of the increased risk. Conclusions-Plaque length seems to be in the pathway between older age and higher risk of S+D among carotid artery stenting-treated patients, but it mediated only 8% of the age effect excess risk of carotid artery stenting in CREST. Other factors and mechanisms underlying the age effect need to be identified as plaque length will not identify elderly patients for whom stenting is safe relative to endarterectomy. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00004732.
R
andomized clinical trials of carotid artery stenting (CAS) have demonstrated that advancing patient age is associated with a higher combined risk of CAS with both periprocedural stroke or death (S+D) [1] [2] [3] [4] and events occurring during follow-up. [5] [6] [7] [8] For patients with high-grade (symptomatic or asymptomatic) carotid stenosis, the primary overall result of the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) showed no difference in the efficacy of treatment with CAS versus carotid endarterectomy (CEA). 5 However, a secondary aim of the study was to assess whether sex, age, or symptomatic status of the patients affected the relative efficacy of the procedures, 9 and age proved to be an effect modifier of treatment efficacy with younger patients having better outcomes with CAS and older patients having better outcomes with endarterectomy (P=0.03). 5 The effect modification of age was subsequently investigated in detail and found to be primarily attributable to an increasing risk of stroke or death (S+D) at older ages among those treated with CAS. 10 Specifically, for those treated with CAS, there was a 76% higher risk of S+D for each 10-year increase in age (hazard ratio [HR], 1.76; 95% confidence interval [CI], 1.35-2.31; P<0.0001), whereas for those treated with CEA, there was a (nonsignificant) 12% increase in risk (HR, 1.16; 95% CI, 0.82-1.54; P=0.47). the higher S+D risk. For example, patients at older ages have been shown to be more likely to have arterial characteristics that may differentially increase the risk of CAS, including greater tortuosity both proximally and distally, unfavorable arch elongation, and arch calcification, 11 and these arterial characteristics may be the factors that place individuals at higher risk. Hence, it may be that it is not age itself, but agerelated changes in the arterial structure or other confounding factors (such as cardiovascular risk factors) that place the patient at higher risk. If this is the case, the age-related changes in arterial structure are in the pathway between the previously documented association of older age and higher stroke or death risk. It is not age itself that places people at higher risk, but rather older age that leads to adverse arterial characteristics that in turn lead to higher risk.
The clinical importance of assessing these relationships is that if factors in the pathway of higher risk in the elderly can be identified, then characterizing the elderly population by the factors that are in the pathway to higher risk may allow the segmentation of the population into those at high risk for CAS complications (those with the factor in the pathway) and those at low risk (those without the factor in the pathway). This would then allow the safe use of CAS among a low-risk subset of elderly patients (and likewise, identify those at high risk where CAS should be avoided).
Others have attempted to identify the safe subset of elderly patients for CAS. 12 Herein, we undertake a more formal mediation analysis to more systematically identify factors potentially in the pathway contributing to higher stroke risk in elderly patients treated with CAS.
Methods
Details of the methods and primary results of CREST have been reported. 5, 9 Participants were enrolled between December 2000 and July 2008 at 117 clinical centers in the United States and Canada. The protocol was approved by the institutional research/ethics review boards at participating sites. All participants provided signed informed consent. The primary end point for CREST was the composite of any stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke within 4 years after randomization. The current analysis used the restricted outcome of periprocedural stroke or death (S+D). The periprocedural period in CREST was defined as 30 days after procedure for those receiving treatment within 30 days of randomization, or 36 days after randomization for those not receiving treatment within 30 days. Because the focus of the analysis is on the risk directly associated with CAS, analysis was performed on the 1123 patients in CREST who were randomized to the procedure and received the procedure within 30 days of randomization (per-protocol population).
The goal of this analysis is to assess whether we can identify the cause for the higher combined S+D risk among older CAS-treated patients. Suppose that some patient or arterial characteristic (such as arterial tortuosity) increases with age and is also associated with higher risk of events in CAS-treated patients, then it is in the pathway for the observed higher risk of CAS at older ages. Mediation analysis has been proposed as an approach to assess whether a factor (such as tortuosity) is in the causal pathway between an exposure (such as age) and an outcome (such as the combined risk of stroke or death), and to assess what proportion of the effect of the exposure (age) on the outcome (risk of stroke or death) is attributable to the specific pathway (tortuosity). 13 For a factor to be a mediator, it must be associated with both the exposure and the outcome, which can be assessed in separate analyses. The degree to which the factor mediates the association between the exposure and the outcome can be assessed by first estimating the magnitude of the association between exposure and outcome without adjustment for the potential mediator, which can be characterized by the HR (or relative risk). Then the potential mediating factor is added to the predictive model, with the change in the magnitude of association between the exposure and the outcome indexing the degree of mediation of the association. As noted in the introduction, for CAS-treated patients in CREST, there is 76% increase in combined risk of S+D for each 10-year difference in age. 10 If the potential mediating factor is the single cause for this increased risk at older ages, then the association between the exposure and the outcome will be eliminated by adjustment for the mediating factor and the HR will be reduced to 1.00. If tortuosity is not in the pathway, the adjustment for the factor will have no effect on the magnitude of the association between exposure and outcome. Finally, if the potential mediating factor contributes some, but not all, of the association between the exposure and the outcome, then adjustment will significantly reduce magnitude of the association, but it will remain significant (for example, the 76% increased risk per decade may be reduced to 38%, reflecting that half of the age-stroke/death association is attributable to tortuosity).
Patient characteristics considered as potential mediators were hypertension, diabetes mellitus, and dyslipidemia. Arterial characteristics were assessed both by the clinical center and at the angiographic core laboratory for the study. Measures assessed from the procedural angiogram by the clinical center staff included plaque length (in millimeters [mm]), whether there was evidence that the plaque was eccentric, whether there was evidence of ulceration, and percent stenosis. Percent stenosis was measured during the procedural angiogram and recorded by the centers using the method used in the North American Symptomatic Carotid Endarterectomy Trial (NASCET). 14 A total of 1042 (93%) of the 1123 patients in the per-protocol population also had their angiogram interpreted by the angiographic core laboratory, where assessments were made on plaque length, width of potential ulcer (no ulcer, narrow mouth, and wide mouth), plaque location (sequential, remote, or contiguous), and tortuosity (none, moderate, or severe). The lesion length was measured as the distance (in millimeters) from the proximal to the distal shoulder of the plaque in the most unforeshortened projection. Lesion length was ordinally ranked as discrete (<5 mm), focal (5-10 mm), tubular (10-20 mm), or diffuse (>30 mm). Ulceration was defined as present when the plaque was noted to have a small crater or lumen flap. A discrete lumen widening in the area of the stenosis is noted, which may extend with a narrow mouth beyond the normal arterial lumen (0=absent; 1=present). The ulceration was coded as narrow mouth (0=absent; 1=present) and by the presence or absence of staining within the ulcer (0=absent; 1=present). Tortuosity was measured both distal and proximal to the lesion. Only 5 subjects (0.5%) had severe tortuosity proximal to the lesion, and 3 of those were also captured as severe distal tortuosity. As such, we focused the analysis on distal tortuosity only. Finally, preprocedural ultrasound assessments were made for 851 of the participants in the ultrasound core laboratory, where the peak systolic velocity was assessed, and analyses for this factor are restricted to this subset.
Results
There were 50 S+D events among the 1123 CAS patients in the study. Table 1 describes characteristics of the study population by age strata, and an assessment of whether there is an association between age and these factors across the age strata. The length of the plaque, whether measured locally or in the core laboratory, was strongly associated with age, with older patients having substantially longer plaque. Likewise, there was an increasing prevalence of tortuosity (as assessed by central laboratory) at older ages. Both of these factors meet the first criterion for potentially being in the pathway between older age and higher S+D risk.
Association of Age With Potential Factors in the Pathway
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However, other factors failed to meet this criterion. Older patients in the study were actually less likely (P<0.05) to have diabetes mellitus, whereas the test for trend showed that hypertension increased with age until the oldest age category where it declined again. Hence, it would have to be argued that being hypertensive or diabetic is protective for these factors to be in the pathway of the age and S+D risk association, making them unlikely candidates to contribute to the age with S+D risk association. Likewise, the prevalence of dyslipidemia, peak systolic velocity measured in the central ultrasound core laboratory, and plaque location measured in the angiography core laboratory were not associated with age. Finally, there was a trend for increasing prevalence of a narrow mouth ulcer (P=0.09); however, the increase was minimal, and the relationship failed to reach statistical significance. Table 2 provides the estimated HR for S+D for each of the factors considered as potentially along the pathway from age to S+D risk, with several factors being associated with higher risk of S+D. Plaque length, whether measured locally or centrally, was associated with higher S+D risk (HR, 1.04 and 1.06 per SD difference; P=0.012). There was higher risk for both eccentric plaque (HR, 2.01; 95% CI, 1.08-3.72) and ulcerated plaque (HR, 2.05; 95% CI, 1.17-3.59) measured locally. In addition, centrally sequential plaque assessed in the core laboratory seemed to be strongly associated with risk of S+D (HR, 2.40; 95% CI, 1.15-5.03).
Association of Potential Factors Along the Pathway to S+D Risk
Several factors were not significantly associated with S+D risk. Specifically, hypertension, diabetes mellitus, dyslipidemia, percent stenosis on procedural angiogram, peak systolic velocity evaluated centrally, and distal tortuosity evaluated centrally were all not significantly related to S+D risk.
Formal Mediation Analysis
Only plaque length evaluated locally significantly mediated the association between age and S+D risk, attenuating the HR from 1.72 (95% CI, 1.26-2.37) to 1.66 (95% CI, 1.20-2.29), a significant reduction in the HR (P=0.039). Although this was a significant attenuation, this represents only an 8.3% reduction in risk ([1.72-1.66]/[1.72-1.00] = 0.083), accounting for a small proportion of the association between age and S+D risk. The association between age and S+D risk remains clearly significant, even accounting for plaque length (HR, 1.66; 95% CI, 1.20-2.29).
No other factor significantly mediated the association between age and S+D risk (P≥0.11), suggesting that these factors are not in the pathway from age to S+D risk.
Discussion
Even before examining the formal mediation analysis provided in Table 3 , we observed that only plaque length (whether locally or centrally measured) was associated with both the exposure (age) and the outcome (S+D risk), and, as such, it is the only factor among those we measured that can be in the pathway from older age to higher S+D risk. Plaque length measured locally proved to significantly mediate the association between age and S+D risk, whereas plaque length measured centrally did not. This is a product of a stronger association between the exposure (age) and the potential mediation factor (plaque length) when locally measured than when centrally measured (P<0.0001 versus P=0.002), and also a stronger association between the potential mediating factor (plaque length) and the outcome (S+D risk) when measured locally than when measured centrally (pathway C shown in Table 2 ; P=0.005 versus P=0.012). These lower levels of significance could reflect the larger sample size of the local reading (n=1123 versus n=1042), or that the local readings were actually more reliable (less noise). Although the centrally assessed plaque length failed to significantly mediate the association between age and S+D risk, it did have the smallest P value of the remaining factors (P=0.11), perhaps suggesting a trend for mediation.
Although there is evidence that the (locally assessed) plaque length is in the pathway of older age and higher S+D risk, the factor accounted for only 8% of the excess risk in older people, attenuating the association from a 72% increased S+D risk per 10 years in age to 66% increased risk per 10 years in age (ie, HR decrease from 1.72 to 1.66). This 66% increased S+D risk with each 10 years of age remained highly significant, suggesting that (1) age has a direct effect on S+D risk, (2) there are other factors related to other pathways not considered in the list of potential factors along the pathway, or (3) plaque length is measured with too much error to reliably account for its effect on the association between age and S+D risk. These observations imply that we were unable to find a factor that could be used to identify older patients, where CAS can be safely used in older patients. Bonati et al 15 also reported on the importance of lesion length, finding it independently associated with periprocedural stroke and death for both CEA-and CAS-treated patients. Naggara et al 16 failed to detect such a relationship for CAS-treated patients, but the sensitivity of their analysis was limited by a smaller number of patients.
The vessel tortuosity did increase at older ages; however, it was not significantly associated with S+D risk. As such, although there is more tortuosity at older ages, as it is not associated with stroke risk, tortuosity as measured in CREST cannot be a contributor to the higher risk at older ages in the trial. A challenge in assessing a relationship between vessel tortuosity and stroke events is that tortuosity is difficult to assess objectively and in a standardized manner.
There were also several factors that did identify higher risk for CAS-treated patients including eccentric plaque, ulcerated plaque, and sequential plaque. However, the focus of this article is not to identify factors associated with higher risk in CAS-treated patients, but rather to help to understand why older patients were at higher stroke risk. None of these factors increased with the age of the patient, and as such it is not surprising that they failed to significantly mediate or attenuate the relationship of older age and higher stroke risk. Our study suggests that eccentric, ulcerated, and sequential plaque put patients at higher risk of stroke or death regardless of age. In other words, there was a greater fear factor associated with eccentric, ulcerated, and sequential plaque than with long plaque, and this caused operators to take added precautions to avoid complications. The focus of this report has been on symptomatic and asymptomatic patients combined. Although event rates in the symptomatic stratum are higher for both CAS and CEA than observed in the asymptomatic stratum, the relative treatment differences for symptomatic versus asymptomatic patients has been consistently similar, and to date, we have not detected a single instance where symptomatic status has acted as an effect modifier (P>0.10). For example, considering the periprocedural risk of stroke or death, the event rates in the asymptomatic stratum were 2.5±0.6% and 1.4±0.5% for CAS and CEA, respectively, for a CAS-to-CEA HR of 1.88 (95% CI, 0.79-4.22). The event rates were higher in the symptomatic stratum, specifically 6.0±0.9% and 3.2±0.7% for CAS and CEA, respectively; however, the CAS-to-CEA HR was strikingly similar to that observed for asymptomatic patients at 1.89 (95% CI, 1.11-3.21). Hence, in this case (as in every other case considered), although the event rates were higher in the symptomatic stratum, the relative treatment difference is similar.
Our analysis has several strengths and weaknesses. Perhaps the greatest strength is the systematic assessment of baseline characteristics (including having both local and central assessment of angiographic characteristics) and the systematic detection and adjudication of stroke events. 5 The greatest weakness is the small number of S+D events (n=50), which implies low power to assess both associations with events and the mediation of these associations. As noted previously, potentially important factors such as difficult aortic arch anatomy, aortic arch disease, and arterial tortuosity proximal to the carotid bifurcation were not assessed. We also did not have data on the composition of the carotid plaques. Study of the plaques in CREST via the several methods available 17 would have provided an opportunity to address potential agerelated changes in plaque composition and possible associations with periprocedural risk. Finally, the absence of baseline magnetic resonance imaging scans eliminated assessment of the role of age-related white matter disease, the presence of which increases periprocedural risk. 18 In conclusion, plaque length seems to be in the pathway between older age and higher risk of stroke or death among CAS-treated patients, but it mediated only 8% of the age effect excess risk of CAS in CREST. Other factors and mechanisms underlying the age effect need to be identified. Plaque length will not identify elderly patients for whom stenting is safe relative to endarterectomy. Rather, even accounting for differences in plaque length, there is a 66% increase in risk of stroke per increased decade of age, implying that CAS should be used cautiously in the elderly (regardless of patient or arterial characteristics). There were also several factors that did identify higher risk for CAS-treated patients, including eccentric plaque, ulcerated plaque, and sequential plaque. However, there was no evidence that the prevalence of these increased with age, making them unlikely to be reasons for higher risk in the elderly. Vessel tortuosity did increase with age; however, tortuosity was not related to increased S+D risk, and thus unlikely to be the reason for higher risk in the elderly. We cannot determine whether there are intrinsic characteristics central to older age or other factors potentially in the pathway that we did not consider in this analysis. Nonetheless, even after adjusting for the 1 factor (plaque length) demonstrated to likely be along the pathway to higher risk in the elderly, the risk in the elderly associated with the use of CAS remained high.
